Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the midpoint. Preliminary imaging data from the study show encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Quantum believes this technique could enhance the development of MS therapies, including its investigational candidate Lucid-MS. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026.
Demyelination is the underlying mechanism of multiple sclerosis, and Lucid-MS is a patented new chemical entity that has been shown to prevent and reverse myelin degradation in preclinical models. The imaging study with Massachusetts General Hospital aims to provide a direct method to visualize demyelination in patients, which could accelerate clinical development of new treatments.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is developing Lucid-MS as its lead compound.
The company also retains ownership of 19.84% of Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets UNBUZZD(TM) as an over-the-counter product. Quantum receives royalty payments of 7% of sales from UNBUZZD(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of rights to develop similar products for pharmaceutical and medical uses.
The achievement of the midpoint enrollment milestone is significant because it brings the study closer to completion, potentially providing critical validation of the imaging technique. If successful, this technique could become a valuable tool for assessing demyelination in MS patients, aiding in diagnosis and treatment monitoring. For the industry, a reliable PET imaging method for demyelination could streamline clinical trials of MS therapies by providing a direct biomarker of drug efficacy.
For patients, improved imaging could lead to earlier detection of MS lesions, including gray matter lesions that are often missed by conventional MRI. This could enable more timely interventions and better management of the disease. The implications for the broader biopharmaceutical sector are substantial, as the ability to directly visualize demyelination may accelerate the development of new treatments for MS and other demyelinating conditions.
Quantum BioPharma's progress in this study underscores its commitment to advancing MS research. The company's newsroom at https://ibn.fm/QNTM provides updates on its developments. For more details on the press release, visit https://ibn.fm/4IZ0y.
